May 15, 2020 / 7:00 PM / 2 months ago

BRIEF-FDA Approves Nivolumab Plus Ipilimumab For First-Line Metastatic Non-Small Cell Lung Cancer

May 15 (Reuters) - U.S. Food and Drug Administration:

* FDA - APPROVES BRISTOL-MYERS SQUIBB’ NIVOLUMAB PLUS IPILIMUMAB FOR FIRST-LINE METASTATIC NON-SMALL CELL LUNG CANCER (PD-L1 TUMOR EXPRESSION ≥1%)

* FDA - APPROVED PD-L1 IHC 28-8 PHARMDX AS A COMPANION DIAGNOSTIC DEVICE FOR SELECTING PATIENTS WITH NSCLC FOR TREATMENT WITH NIVOLUMAB PLUS IPILIMUMAB Source text: (bit.ly/2Ta9I5d) Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below